PHT1-10 Antibody

What is PHT1 and why is it a significant research target?

PHT1 (SLC15A4) is a peptide/histidine transporter expressed primarily in the lysosomes of immune cells, with significant presence in the brain, intestine, and certain tumor cells . Its importance stems from its dual functionality: as a transporter that regulates lysosomal amino acid and oligopeptide levels, and as a scaffolding protein that interacts with key immune signaling components . PHT1 plays a pivotal role in Toll-like receptor (TLR) pathways, mTOR signaling, and type I interferon production, making it particularly relevant to autoimmune disease research, especially systemic lupus erythematosus (SLE) .

What are the standard applications for PHT1 antibodies in research?

PHT1 antibodies are primarily utilized in Western Blot experiments for protein expression analysis . They are also valuable in immunofluorescence studies to confirm the lysosomal localization of PHT1 . In advanced research contexts, these antibodies can be employed in co-immunoprecipitation assays to investigate protein-protein interactions, particularly with signaling molecules like LAMTOR1, LAMTOR2, and TASL . When selecting a PHT1 antibody, researchers should consider the specific epitope recognition properties and validate cross-reactivity with their species of interest.

What are the recommended protocols for PHT1 antibody validation?

A comprehensive validation approach should include:

• Western Blot analysis comparing control (mock-transfected) versus PHT1-expressing cell lysates

• Inclusion of appropriate positive controls (such as V5-tagged proteins for epitope-tagged constructs)

• Optimization of antibody dilution ratios (typically starting with 1:200 for custom PHT1 antibodies)

• Secondary validation through immunofluorescence to confirm subcellular localization patterns

For Western Blot validation specifically, researchers should follow these steps:

• Separate 10-40 μg of total protein by SDS-PAGE (8-10% gels are suitable for PHT1's size)

• Transfer to PVDF membranes

• Block with 5% non-fat dry milk in TBST

• Probe with primary antibody (1:200-1:5000 dilution range, depending on antibody source)

• Apply HRP-conjugated secondary antibody (typical dilution 1:5000)

• Visualize using chemiluminescent detection systems

How can researchers optimize PHT1 antibody performance in lysosomes?

Optimizing PHT1 antibody performance for lysosomal detection requires special considerations due to the acidic, proteolytic environment of lysosomes. Methodological approaches should include:

• Careful sample preparation to preserve lysosomal integrity, using specialized lysis buffers containing protease inhibitors

• Implementation of cellular fractionation protocols to enrich lysosomal membranes before immunodetection

• Adjustment of fixation protocols when performing immunofluorescence (aldehyde-based fixatives generally perform better than alcohol-based ones for maintaining lysosomal structures)

• Co-labeling with established lysosomal markers (LAMP1, LAMP2) to confirm specificity

When isolating lysosomal fractions for PHT1 detection, differential centrifugation followed by density gradient separation yields the best results, with protein expression confirmed by both anti-PHT1 and anti-GFP antibodies (for GFP-tagged constructs) .

What experimental design considerations should researchers address when studying PHT1-TASL interactions?

The interaction between PHT1 and TASL represents a critical junction in immune signaling pathways. When designing experiments to investigate this interaction:

• Consider using cryo-EM techniques to visualize structural conformations of PHT1, as this has been successful in revealing the outward-open conformation

• Implement biochemical approaches combined with structural modeling to understand the binding dynamics between PHT1 and TASL

• Pay particular attention to the first 16 N-terminal residues of TASL, which have been shown to fold into a helical structure that binds within PHT1's central cavity

• Design experiments that can distinguish between the transport function and the adaptor protein recruitment function of PHT1

Research indicates that TASL binding occurs preferentially when PHT1 is in its inward-open conformation, suggesting conformation-dependent interaction dynamics that should be accounted for in experimental design .

How can researchers troubleshoot inconsistent PHT1 antibody results?

Inconsistent results with PHT1 antibodies may stem from multiple factors. A systematic troubleshooting approach should include:

• Antibody validation with positive and negative controls

• Expression level verification through qRT-PCR using gene-specific primers for PHT1

  • Forward: CCAACATCACGCCCTTCG (150 nM)

  • Reverse: ACAGTGGGGATCGCATAA (100 nM)

• Assessment of lysosomal integrity and pH in your experimental model

• Verification of protein loading consistency using housekeeping genes

• Evaluation of post-translational modifications that might affect epitope recognition

Additionally, expression of PHT1 can vary significantly between cell types and tissues, with highest expression reported in skeletal muscle and immune cells . This variability should be considered when interpreting results across different biological systems.

What methodologies are recommended for studying PHT1's role in systemic lupus erythematosus (SLE)?

PHT1 has been implicated in SLE pathogenesis through its effects on type I interferon (IFN-I) production. Researchers investigating this connection should consider:

• Using both in vitro immune cell models and in vivo lupus-prone mouse models

• Implementing CRISPR-Cas9 gene editing to create PHT1 mutants that separate transport function from scaffolding function

• Designing experiments that specifically assess IRF5 activation downstream of PHT1-TASL interaction

• Monitoring both PHT1 expression and localization changes in disease versus control samples

• Studying the effects of pharmacological modulation of PHT1 on disease progression

Recent research suggests that targeting the PHT1-TASL interaction could provide therapeutic avenues for SLE treatment, making this interaction particularly relevant for translational research .

What considerations should be made when designing experiments to study PHT1's transport versus scaffolding functions?

PHT1 exhibits dual functionality as both a transporter and scaffolding protein, which presents unique experimental challenges. To differentiate between these functions:

• Design transport assays using solid-supported membrane-based electrophysiology (SSME) with isolated lysosomal membranes to study PHT1's transport properties in its native environment

• Create mutation studies that specifically target residues involved in substrate binding versus protein-protein interactions

• Implement comparative studies with other POT family members that lack the scaffolding functions of PHT1

• Utilize pH-dependent assays to evaluate histidine transport under varying conditions

Recent functional characterization studies have successfully employed SSME to identify multiple substrates of PHT1, including L-histidine, L-arginine, L-lysine, His-Leu, and Leu-Leu, providing methodological frameworks for such differential analyses .

What are the key differences between various commercially available PHT1 antibodies?

When selecting from the numerous commercially available PHT1 antibodies, researchers should consider several factors:

Currently, there are approximately 92 PHT1 antibodies available across multiple suppliers, with varying specifications and optimized applications . Researchers should request detailed validation data from manufacturers and consider conducting preliminary validation experiments in their specific experimental systems.

How can researchers effectively integrate PHT1 antibody data with other molecular techniques?

A comprehensive research approach to PHT1 function should integrate antibody-based detection with complementary techniques:

• Combine Western Blot protein expression data with qRT-PCR gene expression analysis using validated primer sets

• Integrate immunofluorescence localization studies with live-cell imaging of fluorescently tagged PHT1

• Correlate antibody-detected protein levels with functional transport assays

• Supplement co-immunoprecipitation findings with proximity ligation assays or FRET-based interaction studies

• Consider proteomics approaches to identify novel interaction partners of PHT1 beyond those already characterized (TASL, LAMTOR1/2)

What are the latest methodologies for studying PHT1's role in the IRF5 pathway?

Recent advances in studying PHT1's involvement in IRF5-mediated type I interferon production include:

• Cryo-EM structural analysis of PHT1-TASL complexes to understand binding mechanics

• Development of small molecule inhibitors that specifically disrupt PHT1-TASL interaction without affecting transport function

• Implementation of proximity labeling techniques (BioID, APEX) to identify the complete interactome of PHT1 within the IRF5 pathway

• Single-cell analysis of PHT1 expression and localization in specific immune cell subsets from SLE patients

• Generation of conformation-specific nanobodies (synthetic antibodies) that can distinguish between different functional states of PHT1

These approaches are revealing critical insights into how PHT1 contributes to autoimmune pathologies through its non-canonical signaling functions beyond transport.

How should researchers approach contradictory findings regarding PHT1 function in different experimental systems?

When confronting contradictory results across experimental systems:

• Systematically catalog differences in experimental conditions, including:

  • Cell types and species differences

  • Subcellular localization verification (plasma membrane vs. lysosomal expression)

  • pH conditions of transport assays

  • Post-translational modification status

• Implement standardized positive and negative controls across all experimental systems

• Consider the influence of overexpression systems versus endogenous protein levels

• Evaluate the potential impact of PHT1 mutations or variants (natural or engineered) on experimental outcomes

• Account for differences in antibody recognition specificity across experimental platforms

Research indicates that PHT1 function can vary significantly based on cellular environment and experimental conditions, with particular sensitivity to pH and lysosomal integrity .